Send to

Choose Destination
Eur J Clin Microbiol Infect Dis. 2001 May;20(5):346-9.

Risk factors for esophageal candidiasis in a large cohort of HIV-infected patients treated with nucleoside analogues.

Author information

Institut national de santé et de la recherche médicale SC 10, Hĵpital Paul Brousse, Villejuif, France.


To assess the risk factors for esophageal candidiasis (EC), a cohort study and a case-control study were conducted using 1,368 French patients who were already participating in the Delta trial (which compared different types of antiretroviral therapy in HIV-infected patients) and who had no previous history of EC. During a median follow-up period of 19 months, 87 (6%) patients developed EC. The results of the cohort study showed an increased risk of EC associated with a low baseline CD4+ cell count (P<0.0001), a high baseline plasma HIV RNA level (P < 0.0001) and prior zidovudine therapy (P = 0.02) at entry to the study. The case-control study revealed an increased risk of EC in patients with a recent low CD4+ cell count (P < 0.0002), recent antibacterial chemotherapy (P = 0.01) and oral candidiasis (P < 0.05). Cotrimoxazole prophylaxis also increased the risk of EC (P = 0.04) in the case-control study.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center